ESR1
mutations in PALOMA-3: Results
NC Turner, et al. ASCO 2016
•
ESR1
mutations
were detected in
27%
of the plasma samples tested
•
Of these mutation-positive patients, 38% had polyclonal mutations
•
33% of tumours with
PIK3CA
mutations were also
ESR1
mutation-
positive
In this sub-study of PALOMA-3, HR-positive/HER2-negative mBC patients treated with
fulvestrant + palbociclib had a PFS benefit, irrespective of their
ESR1
genotype
ESR1
positive
ESR1
negative
